6-K ·Filed Apr 22, 2026
Notable filing: 6-K
Actionable Insight • Neutral
Monitor for progression to clinical trials, but preclinical data alone is unlikely to significantly impact stock price given the company's small market cap.
Final — all horizons settled through T+60d
RDHL ▼ -16.77% at T+60d
NEUTRAL call -16.77% · α vs SPY -21.54% · entry $0.8470 → $0.7050
T+1d
+21.61%
call +21.61% · α +22.00%
$1.03
settled 6mo ago
T+5d
+20.43%
call +20.43% · α +20.37%
$1.02
settled 6mo ago
T+20d
+9.56%
call +9.56% · α +6.40%
$0.9280
settled 5mo ago
T+60d
-16.77%
call -16.77% · α -21.54%
$0.7050
settled 3mo ago
Price Chart
Loading chart...
Executive Summary
RedHill Biopharma announced new preclinical data showing opaganib's potential to enhance chemotherapy efficacy in neuroblastoma and boost anti-tumor immunity in triple-negative breast cancer. The data was presented at AACR 2026.
Key Facts
- New preclinical data shows opaganib may enhance oxaliplatin + doxorubicin chemotherapy in high-risk neuroblastoma
- Data shows opaganib may augment anti-tumor immunity in triple-negative breast cancer
- Data presented at AACR 2026
- Opaganib has FDA Orphan Drug and Rare Pediatric Disease designations for neuroblastoma
Financial Impact
Preclinical data only - no revenue impact
revenueepsdebt
Risk Factors
- Preclinical data may not translate to clinical success
- Small market cap makes stock volatile to speculative news
Market Snapshot
Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Investment Themes
Biotech & Drug Discovery
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001178913-26-002177 |
| Document: 0001178913-26-002177-index-headers.html | 0001178913-26-002177 |
| Document: 0001178913-26-002177-index.html | 0001178913-26-002177 |
| Document: 0001178913-26-002177.txt | 0001178913-26-002177 |
27 reports for RDHL
88% Hit rate @ T+60 Went positive at some point 10 of 12 best @ T+60▲ +40.60%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | 6-K | $0.4550 | awaiting T+60 | — | $0.4230 (−7.03%) |
Oct 19, 2026 7d ago | 6-K | $0.5012 | awaiting T+60 | — | $0.4230 (−15.60%) |
Oct 19, 2026 7d ago | Press Release | $0.5012 | awaiting T+60 | — | $0.4230 (−15.60%) |
Oct 13, 2026 12d ago | 6-K | $0.4862 | awaiting T+60 | — | $0.4230 (+13.00%) |
Oct 13, 2026 12d ago | 424B5 | $0.4862 | awaiting T+60 | — | $0.4230 (+13.00%) |
Oct 7, 2026 19d ago | 6-K | $0.4740 | awaiting T+60 | — | $0.4230 (−10.76%) |
Sep 1, 2026 7w ago | 6-K | $0.8700 | awaiting T+60 | — | $0.4230 (−51.38%) |
Aug 31, 2026 8w ago | 6-K | $0.9000 | awaiting T+60 | — | $0.4230 (−53.00%) |
Aug 7, 2026 11w ago | 6-K | $0.6050 | awaiting T+60 | — | $0.4230 (−30.08%) |
Aug 6, 2026 11w ago | 6-K | $0.5810 | awaiting T+60 | — | $0.4230 (−27.19%) |
Showing 10 of 27
US Market Status
Market Closed — Opens in 20m
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers